Posters

    Genotoxicity Of The Gas/Vapor Phase (GVP) Of Cigarette Mainstream Smoke In The Mouse Lymphoma TK Assay (MLA)

    Wittke, S.; Trelles-Sticken, E.
    Conference date
    Mar 7, 2011
    Conference name

    Society of Toxicology (SOT) 2011
    Link to more information
    Topic
    Summary

    The in vitro mammalian mutagenicity of cigarette smoke by means of the Mouse Lymphoma TK assay (MLA) is generally assessed by assaying the particulate phase only (Schramke et al., 2006). In order to generate a comprehensive and thus more relevant image of cigarette-smoke-related mammalian mutagenicity in vitro we extended this approach to the water-soluble fraction of the gas/vapor phase (GVP). The GVP of mainstream smoke from the reference cigarette 3R4F was assayed in the microtiter plate version (Cole et al., 1986) of the MLA with and without metabolic activation (S9), after 4 and 24 hours of treatment time and 2 and 3 days of expression time. Dose response: a clear-cut positive dose-response relationship was seen regardless of activation conditions, treatment time, and expression time. Variability of mutant frequency: For the 24-h treatment time (without S9, 2 days expression), mean repeatability was 16% and mean reproducibility was 26%. For the 4-h treatment time (with and without S9, 3 days expression), mean repeatability was 12% and mean reproducibility was 15%. Variability of 1/C3B values: For the 24-h treatment time (without S9, 2 days expression), repeatability was 6% and reproducibility was 8%. For the 4-h treatment time (with and without S9, 3 days expression), mean repeatability was 3% and mean reproducibility was 5%. Thus, the results showed that the MLA is sensitive for the detection of the in vitro mammalian mutagenicity of the gas/vapor phase of cigarette mainstream smoke. 

    Related Publications

    A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

    Pre-clinical Toxicology

    Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

    Pre-clinical Toxicology

    Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

    Pre-clinical Toxicology

    Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

    Pre-clinical Toxicology

    Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

    Pre-clinical Toxicology

    Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

    Pre-clinical Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.